O	0	8	Adjuvant
O	9	18	docetaxel
O	19	22	for
O	23	27	node
O	27	28	-
O	28	36	positive
O	37	43	breast
O	44	50	cancer
O	50	51	.

O	52	54	We
O	55	63	compared
B-intervention	64	73	docetaxel
I-intervention	74	78	plus
I-intervention	79	90	doxorubicin
I-intervention	91	94	and
I-intervention	95	111	cyclophosphamide
I-intervention	112	113	(
I-intervention	113	116	TAC
I-intervention	116	117	)
O	118	122	with
B-control	123	135	fluorouracil
I-control	136	140	plus
I-control	141	152	doxorubicin
I-control	153	156	and
I-control	157	173	cyclophosphamide
I-control	174	175	(
I-control	175	178	FAC
I-control	178	179	)
O	180	182	as
O	183	191	adjuvant
O	192	204	chemotherapy
O	205	208	for
O	209	217	operable
O	218	222	node
O	222	223	-
O	223	231	positive
O	232	238	breast
O	239	245	cancer
O	245	246	.

O	247	249	We
O	250	258	randomly
O	259	267	assigned
B-total-participants	268	272	1491
B-eligibility	273	278	women
I-eligibility	279	283	with
I-eligibility	284	292	axillary
I-eligibility	293	297	node
I-eligibility	297	298	-
I-eligibility	298	306	positive
I-eligibility	307	313	breast
I-eligibility	314	320	cancer
O	321	323	to
O	324	327	six
O	328	334	cycles
O	335	337	of
O	338	347	treatment
O	348	352	with
O	353	359	either
O	360	363	TAC
O	364	366	or
O	367	370	FAC
O	371	373	as
O	374	382	adjuvant
O	383	395	chemotherapy
O	396	401	after
O	402	409	surgery
O	409	410	.

O	411	414	The
O	415	422	primary
O	423	426	end
O	427	432	point
O	433	436	was
B-outcome-Measure	437	444	disease
I-outcome-Measure	444	445	-
I-outcome-Measure	445	449	free
I-outcome-Measure	450	458	survival
O	458	459	.

O	460	462	At
O	463	464	a
O	465	471	median
O	472	478	follow
O	478	479	-
O	479	481	up
O	482	484	of
O	485	487	55
O	488	494	months
O	494	495	,
O	496	499	the
O	500	509	estimated
O	510	515	rates
O	516	518	of
B-outcome	519	526	disease
I-outcome	526	527	-
I-outcome	527	531	free
I-outcome	532	540	survival
I-outcome	541	543	at
I-outcome	544	548	five
I-outcome	549	554	years
O	555	559	were
B-iv-bin-percent	560	562	75
I-iv-bin-percent	563	570	percent
O	571	576	among
O	577	580	the
B-intervention-participants	581	584	745
O	585	593	patients
O	594	602	randomly
O	603	611	assigned
O	612	614	to
O	615	622	receive
O	623	626	TAC
O	627	630	and
B-cv-bin-percent	631	633	68
I-cv-bin-percent	634	641	percent
O	642	647	among
O	648	651	the
B-control-participants	652	655	746
O	656	664	randomly
O	665	673	assigned
O	674	676	to
O	677	684	receive
O	685	688	FAC
O	688	689	,
O	690	702	representing
O	703	704	a
O	705	707	28
O	708	715	percent
O	716	725	reduction
O	726	728	in
O	729	732	the
O	733	737	risk
O	738	740	of
O	741	748	relapse
O	749	750	(
O	750	751	P
O	751	752	=
O	752	753	0
O	753	754	.
O	754	757	001
O	757	758	)
O	759	761	in
O	762	765	the
O	766	769	TAC
O	770	775	group
O	775	776	.

O	777	780	The
O	781	790	estimated
O	791	796	rates
O	797	799	of
B-outcome	800	807	overall
I-outcome	808	816	survival
I-outcome	817	819	at
I-outcome	820	824	five
I-outcome	825	830	years
O	831	835	were
B-iv-bin-percent	836	838	87
I-iv-bin-percent	839	846	percent
O	847	850	and
B-cv-bin-percent	851	853	81
I-cv-bin-percent	854	861	percent
O	861	862	,
O	863	875	respectively
O	875	876	.

O	877	886	Treatment
O	887	891	with
O	892	895	TAC
O	896	904	resulted
O	905	907	in
O	908	909	a
B-iv-bin-percent	910	912	30
I-iv-bin-percent	913	920	percent
B-outcome	921	930	reduction
I-outcome	931	933	in
I-outcome	934	937	the
I-outcome	938	942	risk
I-outcome	943	945	of
I-outcome	946	951	death
O	952	953	(
O	953	954	P
O	954	955	=
O	955	956	0
O	956	957	.
O	957	960	008
O	960	961	)
O	961	962	.

O	963	966	The
O	967	976	incidence
O	977	979	of
B-outcome	980	985	grade
I-outcome	986	987	3
I-outcome	988	990	or
I-outcome	991	992	4
I-outcome	993	1004	neutropenia
O	1005	1008	was
B-iv-bin-percent	1009	1011	65
I-iv-bin-percent	1011	1012	.
I-iv-bin-percent	1012	1013	5
I-iv-bin-percent	1014	1021	percent
O	1022	1024	in
O	1025	1028	the
O	1029	1032	TAC
O	1033	1038	group
O	1039	1042	and
B-cv-bin-percent	1043	1045	49
I-cv-bin-percent	1045	1046	.
I-cv-bin-percent	1046	1047	3
I-cv-bin-percent	1048	1055	percent
O	1056	1058	in
O	1059	1062	the
O	1063	1066	FAC
O	1067	1072	group
O	1073	1074	(
O	1074	1075	P
O	1075	1076	<
O	1076	1077	0
O	1077	1078	.
O	1078	1081	001
O	1081	1082	)
O	1082	1083	;
O	1084	1089	rates
O	1090	1092	of
B-outcome	1093	1100	febrile
I-outcome	1101	1112	neutropenia
O	1113	1117	were
B-iv-bin-percent	1118	1120	24
I-iv-bin-percent	1120	1121	.
I-iv-bin-percent	1121	1122	7
I-iv-bin-percent	1123	1130	percent
O	1131	1134	and
B-cv-bin-percent	1135	1136	2
I-cv-bin-percent	1136	1137	.
I-cv-bin-percent	1137	1138	5
I-cv-bin-percent	1139	1146	percent
O	1146	1147	,
O	1148	1160	respectively
O	1161	1162	(
O	1162	1163	P
O	1163	1164	<
O	1164	1165	0
O	1165	1166	.
O	1166	1169	001
O	1169	1170	)
O	1170	1171	.

B-outcome	1172	1177	Grade
I-outcome	1178	1179	3
I-outcome	1180	1182	or
I-outcome	1183	1184	4
I-outcome	1185	1195	infections
O	1196	1204	occurred
O	1205	1207	in
B-iv-bin-percent	1208	1209	3
I-iv-bin-percent	1209	1210	.
I-iv-bin-percent	1210	1211	9
I-iv-bin-percent	1212	1219	percent
O	1220	1222	of
O	1223	1226	the
O	1227	1235	patients
O	1236	1239	who
O	1240	1248	received
O	1249	1252	TAC
O	1253	1256	and
B-cv-bin-percent	1257	1258	2
I-cv-bin-percent	1258	1259	.
I-cv-bin-percent	1259	1260	2
I-cv-bin-percent	1261	1268	percent
O	1269	1271	of
O	1272	1277	those
O	1278	1281	who
O	1282	1290	received
O	1291	1294	FAC
O	1295	1296	(
O	1296	1297	P
O	1297	1298	=
O	1298	1299	0
O	1299	1300	.
O	1300	1302	05
O	1302	1303	)
O	1303	1304	;
B-outcome	1305	1307	no
I-outcome	1308	1314	deaths
O	1315	1323	occurred
O	1324	1326	as
O	1327	1328	a
O	1329	1335	result
O	1336	1338	of
O	1339	1348	infection
O	1348	1349	.

B-iv-bin-abs	1350	1353	Two
O	1354	1362	patients
O	1363	1365	in
O	1366	1370	each
O	1371	1376	group
B-outcome	1377	1381	died
O	1382	1388	during
O	1389	1398	treatment
O	1398	1399	.

B-outcome	1400	1410	Congestive
I-outcome	1411	1416	heart
I-outcome	1417	1424	failure
I-outcome	1425	1428	and
I-outcome	1429	1434	acute
I-outcome	1435	1442	myeloid
I-outcome	1443	1451	leukemia
O	1452	1460	occurred
O	1461	1463	in
O	1464	1468	less
O	1469	1473	than
B-iv-bin-percent	1474	1475	2
I-iv-bin-percent	1476	1483	percent
O	1484	1486	of
O	1487	1490	the
O	1491	1499	patients
O	1500	1502	in
O	1503	1507	each
O	1508	1513	group
O	1513	1514	.

B-outcome	1515	1522	Quality
I-outcome	1522	1523	-
I-outcome	1523	1525	of
I-outcome	1525	1526	-
I-outcome	1526	1530	life
I-outcome	1531	1537	scores
O	1538	1547	decreased
O	1548	1554	during
O	1555	1567	chemotherapy
O	1568	1571	but
O	1572	1580	returned
O	1581	1583	to
O	1584	1592	baseline
O	1593	1599	levels
O	1600	1605	after
O	1606	1615	treatment
O	1615	1616	.

O	1617	1625	Adjuvant
O	1626	1638	chemotherapy
O	1639	1643	with
O	1644	1647	TAC
O	1647	1648	,
O	1649	1651	as
O	1652	1660	compared
O	1661	1665	with
O	1666	1669	FAC
O	1669	1670	,
O	1671	1684	significantly
O	1685	1693	improves
O	1694	1697	the
O	1698	1703	rates
O	1704	1706	of
O	1707	1714	disease
O	1714	1715	-
O	1715	1719	free
O	1720	1723	and
O	1724	1731	overall
O	1732	1740	survival
O	1741	1746	among
O	1747	1752	women
O	1753	1757	with
O	1758	1766	operable
O	1767	1771	node
O	1771	1772	-
O	1772	1780	positive
O	1781	1787	breast
O	1788	1794	cancer
O	1794	1795	.
